Advertisement Fragment Screening - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about ZoBio

Fragment Screening

ZoBio

ZoBio offers its proprietary TINS technology for ligand screening studies on our own fragment library or the customer’s. TINS is a powerful approach to hit discovery that has been validated on a wide range of pharmaceutically relevant targets.

TINS uses a sample of the target protein and a reference protein that have been immobilized on sepharose based resin. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. The screen is carried out by repeated cycles of fragment application, assaying for binding and fragment removal. TINS is a powerful approach to hit discovery that has been validated on a wide range of targets including epigenetic targets, viral proteins, proteases, kinases, PPI targets, molecular chaperones and membrane proteins including GPCRs and ligand gated ion channels. A typical TINS hit discovery project including a feasibility phase is completed in 1-2 months.

Quick Contact Fragment Screening